APO RESEARCH · REPORT
Soliris (Eculizumab)
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Product & engineering
Understand the product.
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
Selected research
Industry Growth & Trends
Global Soliris (Eculizumab) Industry Growth and Trends Forecast to 2032
Market perspective
Eculizumab, sold under the trade name Soliris, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PHN) and atypical hemolytic uremic syndrome (aHUS). It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted on the basis of small clinical trials.
According to APO Research, the global Soliris (Eculizumab) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Soliris (Eculizumab) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Soliris (Eculizumab) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Soliris (Eculizumab) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Soliris (Eculizumab).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Soliris (Eculizumab) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Soliris (Eculizumab) Market by Company
Alexion
Soliris (Eculizumab) Segment by Type
Plasma Exchange
Plasma Infusion
Soliris (Eculizumab) Segment by Application
PNH
aHUS
Others
Soliris (Eculizumab) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Soliris (Eculizumab) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Soliris (Eculizumab) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Soliris (Eculizumab).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Soliris (Eculizumab) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Plasma Exchange
- Plasma Infusion
Applications
- PNH
- aHUS
- Others
Companies covered
- Alexion
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Soliris (Eculizumab) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Soliris (Eculizumab) Market Size by Region (2021-2032)
- 1.4.1 Global Soliris (Eculizumab) Market Size by Region (2021-2026)
- 1.4.2 Global Soliris (Eculizumab) Market Size by Region (2027-2032)
- 1.5 Key Regions Soliris (Eculizumab) Market Size (2021-2032)
- 1.5.1 North America Soliris (Eculizumab) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Soliris (Eculizumab) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Soliris (Eculizumab) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Soliris (Eculizumab) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Soliris (Eculizumab) Market Size Growth Rate (2021-2032)
2 Soliris (Eculizumab) Market by Type
- 2.1 Type Introduction
- 2.1.1 Plasma Exchange
- 2.1.2 Plasma Infusion
- 2.2 Global Soliris (Eculizumab) Market Size by Type
- 2.2.1 Global Soliris (Eculizumab) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Soliris (Eculizumab) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Soliris (Eculizumab) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Soliris (Eculizumab) Market Size by Regions
- 2.3.1 North America Soliris (Eculizumab) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Soliris (Eculizumab) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Soliris (Eculizumab) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Soliris (Eculizumab) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Soliris (Eculizumab) Market Size Breakdown by Type (2021-2026)
3 Soliris (Eculizumab) Market by Application
- 3.1 Type Introduction
- 3.1.1 PNH
- 3.1.2 aHUS
- 3.1.3 Others
- 3.2 Global Soliris (Eculizumab) Market Size by Application
- 3.2.1 Global Soliris (Eculizumab) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Soliris (Eculizumab) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Soliris (Eculizumab) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Soliris (Eculizumab) Market Size by Regions
- 3.3.1 North America Soliris (Eculizumab) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Soliris (Eculizumab) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Soliris (Eculizumab) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Soliris (Eculizumab) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Soliris (Eculizumab) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Soliris (Eculizumab) Industry Trends
- 4.2 Soliris (Eculizumab) Industry Drivers
- 4.3 Soliris (Eculizumab) Industry Opportunities and Challenges
- 4.4 Soliris (Eculizumab) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Soliris (Eculizumab) Revenue (2021-2026)
- 5.2 Global Soliris (Eculizumab) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Soliris (Eculizumab) Key Company Headquarters & Area Served
- 5.4 Global Soliris (Eculizumab) Company, Product Type & Application
- 5.5 Global Soliris (Eculizumab) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Soliris (Eculizumab) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Soliris (Eculizumab) Players Market Share by Revenue in 2025
- 5.6.3 2025 Soliris (Eculizumab) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Alexion
- 6.1.1 Alexion Company Information
- 6.1.2 Alexion Business Overview
- 6.1.3 Alexion Soliris (Eculizumab) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Alexion Soliris (Eculizumab) Product Portfolio
- 6.1.5 Alexion Recent Developments
7 North America
- 7.1 North America Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Soliris (Eculizumab) Market Size by Country (2021-2026)
- 7.3 North America Soliris (Eculizumab) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Soliris (Eculizumab) Market Size by Country (2021-2026)
- 8.3 Europe Soliris (Eculizumab) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Soliris (Eculizumab) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Soliris (Eculizumab) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Soliris (Eculizumab) Market Size by Country (2021-2026)
- 10.3 South America Soliris (Eculizumab) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Soliris (Eculizumab) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Soliris (Eculizumab) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Soliris (Eculizumab) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst